University of Arkansas, Fayetteville

ScholarWorks@UARK
Biological Sciences Undergraduate Honors
Theses

Biological Sciences

5-2020

Structural and Functional Characterization of Mitochondria with
tRNA Mutations
Brooke Henry

Follow this and additional works at: https://scholarworks.uark.edu/biscuht
Part of the Cell Biology Commons, Molecular Biology Commons, and the Nutritional and Metabolic
Diseases Commons

Citation
Henry, B. (2020). Structural and Functional Characterization of Mitochondria with tRNA Mutations.
Biological Sciences Undergraduate Honors Theses Retrieved from https://scholarworks.uark.edu/
biscuht/31

This Thesis is brought to you for free and open access by the Biological Sciences at ScholarWorks@UARK. It has
been accepted for inclusion in Biological Sciences Undergraduate Honors Theses by an authorized administrator of
ScholarWorks@UARK. For more information, please contact scholar@uark.edu.

Structural and Functional Characterization of Mitochondria with tRNA Mutations

An Honors Thesis submitted in partial fulfilment of the requirement of Honors Studies
in Biology

By

Brooke Henry

Spring 2020
Biology
J. William Fulbright College of Arts and Sciences.
The University of Arkansas

Acknowledgements

I wish to thank everyone who has aided in my research project, though they all
may not be named. I wish to acknowledge their contributions, as they are highly
appreciated. I am deeply grateful for the following:
Dr. Shilpa Iyer for allowing me to work in her lab and providing me the
opportunity to pursue a research project under her mentorship. Ajibola B. Bakare and
Joshua Stabach for their constant support and direction in my research.
I am grateful for the University of Arkansas Honors College, the University of
Arkansas Department of Biology for the opportunity and support to conduct
undergraduate research.
I am grateful to the United States Department of Defense for providing funding of
my project.
I am grateful to Dr. Shilpa Iyer, Dr. Michael Lehmann, Dr. Frank Millet, and Dr.
Susan M. Marren for their willingness to serve on my thesis committee.
Finally, I would like to thank my family and friends for supporting me throughout
this project and my academic career.

2

Table of Contents
Acknowledgements……………………………………………………………...2
Abstract………………………………………………………………………….4
Abbreviations……………………………………………………………………5
Introduction……………………………………………………………………..6
Methods and Materials………………………………………………………….10
Results…………………………………………………………………………..15
Discussion………………………………………………………………………24
Supplementary Figures…………………………………………………………27
Bibliography……………………………………………………………………29

3

Abstract

Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS)
is one of the most common disorders associated with mitochondrial tRNA mutations.
One of the most common causes of MELAS is mutation in the MT-TL1 gene which
codes for mitochondrial tRNA Leucine (UUR). Mutation in MT-TE gene, another
mitochondrial gene which encodes for mitochondrial tRNA Glutamate (GAA/G), has
been implicated in various mitochondrial related myopathies. It remains unclear how
point mutations in these tRNA genes result in disease onset and progression. Here, we
report an early comparative analysis of fibroblast cell lines derived from patients carrying
two different tRNA mutations: m.3243A>G and m.14739G>A. This study examines the
relationship between mitochondrial structure and function as it relates to disease onset
and severity. Morphological analysis revealed differences in network structure between
the tRNA mutant and control cell lines. This was correlated with a decrease in
mitochondrial function as indicated by aberrant mitochondrial membrane potential and
Reactive Oxygen species production. Results from this study suggest that mitochondrial
tRNA mutations can result in dysregulation of mitochondrial morphology, consequently
affecting mitochondrial function.
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Abbreviations

mtDNA

Mitochondrial Deoxyribonucleic acid

tRNA

Transfer RNA

ATP

Adenine Tri-Phosphate

tRNA

Transfer RNA

FCCP

Carbonyl cyanide p- (tri-fluromethoxy) phenyl-hydrazone

MEM

Minimal Essential Media

mt-tRNA-Leu

Mitochondrial tRNA specific for Leucine

mt-tRNA-Glu

Mitochondrial tRNA specific for Glutamic Acid

MMP

Mitochondrial Membrane Potential

ROS

Reactive Oxygen Species

dPBS

Dulbecco’s Phosphate Buffered Saline

TMRE

Tetramethylrhodamine, ethyl ester

ROI

Region of interest
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Introduction
Mitochondria are important to many cellular functions including ATP synthesis,
apoptosis, calcium buffering, and reactive oxygen species production. Mitochondria
contain their own DNA (mtDNA), but the majority of mitochondrial proteins are
synthesized by nuclear DNA (El-Hattab, Adesina, Jones, & Scaglia, 2015). Mutations in
either the mitochondrial DNA (mtDNA) or nuclear DNA regions related to mitochondrial
function can cause disease. The phenotype of mitochondrial disease varies widely
depending on the nature of the genetic mutation. The type of mutations that this paper
will focus on are those that affect transfer RNAs (tRNAs) in the mitochondria. tRNA
mutations make up 10% of the mtDNA genome but are present in 60% of adults with a
mtDNA disease (Queen, Steyn, Lord, & Elson, 2017).
The mitochondrial genome encodes 22 tRNAs, one for each amino acid and a
second for both the tRNA for Leucine and the tRNA for Serine (Scaglia & Wong, 2008).
tRNA encoded by the mitochondrial genome exhibits similar functions to nuclearencoded tRNA (Queen et al., 2017); they bring amino acids to the ribosomal complex in
order to synthesize proteins (Scaglia & Wong, 2008). tRNA molecules maintain a
secondary structure of a clover leaf which then folds to form an L-shape. This 3D Lshape is held together by tertiary interactions (Queen et al., 2017). This structure allows
the tRNA to carry out its functions within the cell.
In this study, we sought to understand the effect of tRNA mutations on
mitochondrial structure and function using two human fibroblast cell lines with
mitochondrial tRNA mutations as our model. The first (SBG6) is the m.3243A>G
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mutation in which a guanine base has been substituted by an adenine base at the
mitochondrial genome location 3243. This nucleotide equates to nucleotide 14 within the
mitochondrial tRNA molecule for the amino acid Leucine (mt-tRNA-Leu(UUR)) (Queen
et al., 2017). This error leads to Mitochondrial encephalopathy, lactic acidosis, and
stroke-like episodes, or MELAS syndrome, one of the most frequent maternally inherited
diseases (El-Hattab et al., 2015). This disease has two categories: one with frequent
seizures, headaches, and vomiting, while the other may include high lactic acid buildup
and myopathy. This mutation is present in 80% of MELAS patients (El-Hattab et al.,
2015). Interactions between bases in tRNA is very important for maintaining the tertiary
structure. The m.3243A>G mutation alters the tertiary structure of mt-tRNA-Leu(UUR),
which impairs mitochondrial translation (Queen et al., 2017) and decreases overall
mitochondrial respiration. The second cell line (SBG7) is m.14739G>A. At location
14739 in the mitochondrial genome, the guanine has been replaced by an adenine. This
mutation affects the function of the tRNA specific for glutamic acid (mt-tRNA-Glu) by
unknown mechanisms to cause mitochondrial pathology. These tRNA mutations can in
turn affect many respiratory chain enzymes, leading to diseased phenotypes (Koga,
Hodges, Markin, & Gorman, 1995).

Fibroblast Sample

Gene affected

tRNA Affected

Mutation

Control (BJSI)

Normal

N/A

N/A

SBG6

MT-TL1

mt-tRNA-Leu (UUR)

m.3243A>G

SBG7

MT-TE

mt-tRNA-Glu (GAA/G)

m.14739G>A

Table 1. Cell lines and their corresponding mutations. Table showing diseased and
control cell lines with their corresponding mutation and which tRNA is affected
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Mitochondria go through rounds of fission and fusion to maintain metabolic
demands of cells. (Ni, Williams, & Ding, 2015). Mitochondrial fission is the division of
one mitochondrion into two daughter mitochondria, whereas fusion combines two
mitochondria into one mitochondrion. These processes must be in balance in order to
have a well-functioning mitochondrial network. It has been suggested that the diseased
mitochondria may have activated fission or deactivated fusion so that the damaged
mitochondria will not be able to incorporate back into the mitochondrial network (Ni et
al., 2015). A hyper-fused mitochondrial network or a fragmented mitochondrial network
indicates an imbalance in fission and fusion cycles, which can an indication of
mitochondrial disease. In this study, a novel technique, Mitochondrial Network Analysis
(MiNA) was used to characterize mitochondrial morphology in diseased and control
fibroblast cell lines.
We hypothesize that these diseased cell lines will display an altered morphology,
with a subsequent alteration in mitochondrial function. Functional analysis of
mitochondria was assessed by recording Mitochondrial Membrane Potential (MMP) and
Mitochondrial Reactive Oxygen Species (mitoROS) production in diseased and healthy
control fibroblast cell lines. Mitochondria maintain a membrane potential across the inner
mitochondrial membrane in order to drive ATP synthesis (Cadenas, 2018). The
complexes of the respiratory chain create this gradient by pumping protons across the
inner mitochondrial membrane (Chen, 1988). This study uses mitochondrial inhibitors
FCCP (Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone; Sigma, U.S.A) and
Oligomycin to create an environment of mitochondrial stress. FCCP is a potent
mitochondrial uncoupler. It uncouples oxidation and phosphorylation by destabilizing the
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proton gradient (Brennan et al., 2006). Oligomycin inhibits ATP synthase by blocking its
proton channel, subsequently hyperpolarizing the mitochondria (Fernyhough &
McGavock, 2014).
Mitochondria are considered the main source of cellular ROS, with superoxide
(O2•−) as the primary type (Murphy, 2009). ROS are important for redox signaling, but
can also cellular damage. Superoxide is produced by a one-electron reduction of oxygen
(O2) and is predominantly produced by Complex I and Complex III of the respiratory
chain (Murphy, 2009). Complex I reduces NADH into NAD+ and passes two electrons to
ubiquinone. It also pumps four protons across the inner mitochondrial membrane.
Complex III passes electrons to cytochrome C and also pumps four protons across the
inner membrane (Nicholls & Ferguson, 2013). This study uses mitochondrial inhibitors
Rotenone and Antimycin A to induce mitochondrial stress. Rotenone inhibits Complex I
near the binding site for ubiquinone, so electrons cannot be further passed down the
electron transport chain. It has been shown to increase ROS production from Complex I
(Gupta & Milatovic, 2014). Antimycin A inhibits the Qi center of Complex III and has
been shown to release ROS inside and outside of the mitochondria (Quinlan, Treberg, &
Brand, 2011).
Our results suggest that the morphology of the mitochondrial network is altered in
tRNA mutants, but it is unclear if it exhibits a hyper-fused or hyper-fragmented
morphology. Functional analysis suggests that tRNA mutant cell lines display decreased
function in regard to mitochondrial membrane potential, but ROS production is unclear.
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Methods and Materials
Cell Culture:
Control and diseased fibroblast cell (see Table 1) lines were thawed and maintained in
culture until passage 8. All cells were maintained in Minimal Essential Media (Gibco,
U.S.A) supplemented with 10% Fetal Bovine Albumin (Hyclone, U.S.A) and 2mM LGlutamine (Thermo Fisher Scientific , U.S.A). Cells were cultured and maintained at
37oC in a humidified atmosphere of 5% CO2 following established protocols.

Cell Imaging:
A day prior to experiment, cells were seeded in 35 mm2 dishes and incubated overnight.
On the day of the experiment, culture media was aspirated and cells were washed with
dPBS (Dulbecco’s Phosphate Buffered Saline). The FCCP (Sigma, U.S.A) treatment
group was treated with 0.7 µM FCCP solution and incubated (in a 37oC, 5% CO2
incubator) for 30 minutes. The media was then aspirated off and 150nM MitoTracker Red
CM-H2Xros (Thermo Fisher Scientific, U.S.A) was added, followed by 30 minutes of
incubation. Cells were washed again with dPBS and Nucblue (Thermo Fisher Scientific,
U.S.A) solution (nuclear stain) was added, followed by an additional 20 minutes of
incubation. At the end of the incubation period, cells were washed with 2-3 times with
dPBS to remove excess stain. Fluorescent and phase contrast images were acquired at
40X magnification for each dish and cell line using EVOS FL microscope. The images
were taken under red fluorescent protein (RFP; 60% and 250ms exposure and exposure
time), DAPI (20% and 120ms), and phase contrast channels. Approximately 5-7 images
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were taken per dish, with 5 dishes per cell line and treatment group. These images were
saved for further analysis.

Mitochondrial Network Analysis (MiNA) using ImageJ

Figure 1. Visual diagram of MiNA procedure. Representation of staining and imaging
fibroblast cells using MitoTracker Red CM-H2Xros, followed by analysis using the
MiNA ImageJ protocol.
Cell images were analyzed using the NIH’s open source image analysis software ImageJ.
This allows the intensity of the stain in cell images to be converted to numerical data.
Processing of the images involved subtracting the background, enhancing local contrast,
making the image binary, and skeletonizing (see Figure 1). This converts the cell image
into a 2-dimensional map of the mitochondrial network. Adobe Photoshop CC 2018 was
used to isolate individual cells. The individual cell skeletons were then analyzed using the

11

Mitochondrial Network Analysis (MiNA) plugin for ImageJ. This software creates
numerical data related to the morphology of the mitochondria. The parameters include
mitochondrial individuals, networks, mean branch length, mean network size (see Table
2). Total respiring mitochondria was calculated by adding the number of individuals to
number of networks. Each cell was outlined in ImageJ to determine its area. The MiNA
parameter values for each cell were divided by the total cell area in order to normalize the
data. Mean and standard deviation (S.D) were calculated from the data. Values outside of
the 2S.D range were excluded from the data set as outliers.
MiNA Parameter

Definition

Individuals

Number of objects without nodes

Networks

Number of objects with at least one node

Mean Branch Length

Average length of branches

Mean Network Size

Average number of branches per network.

Table 2. MiNA parameters and definitions. Table showing each MiNA parameter
along with its respective definition (Valente, Maddalena, Robb, Moradi, & Stuart, 2017).
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Flow cytometry:

a.

b.

Figure 2. Visual diagram of flow cytometry procedure and data analysis.
Representation of flow cytometry protocol (a) including cell culture, treatment, and
preparation. Representation of data analysis using FlowJo (b) including gating the live
cells, creating a histogram, and performing geometric mean to measure mean fluorescent
intensity.

Cells were grown until approximately 80% confluence. On the day of the experiment,
cells were enzymatically detached and divided into their respective treatment groups. The
treatment groups for the membrane potential (MMP) experiments are as follows: NonTreated, TMRE (Tetramethylrhodamine, ethyl ester; Abcam, U.S.A) only,
TMRE+FCCP, and TMRE +Oligomycin (Sigma, U.S.A). The final well concentrations
of 50nM TMRE, 20µM FCCP, and 5µ M Oligomycin were applied to the respective
13

cells. The treatment groups for mitochondrial Reactive Oxygen Species (mitoROS)
experiments are as follows: Non-treated, MitoSox (Thermo Fisher Scientific,
U.S.A)only, MitoSox+Rotenone, and MitoSox+AntimycinA). Final well concentrations
of 3µM MitoSox, 5µM Rotenone, and 5µM AntimycinA were applied to the respective
cells.
In both the MMP and MitoROS experiments, the cells were treated with the respective
mitochondrial inhibitors (FCCP, Oligomycin, Rotenone, and AntimycinA) 10mins prior
to treatment with either TMRE (MMP) or MitoSox (MitoROS). After which incubation
for 25mins followed. At the end of the incubation period, cells were centrifuged and
resuspended in dPBS to get rid of excess stain. The cells were centrifuged a second time
and resuspended in phenol-Red free MEM and transferred to Accuri C6 Flow cytometer
for data acquisition, 10, 000 events was recorded for each well. Flow cytometry data was
analyzed using FlowJo_V10 software. The non-treated group was used to gate for live
cells and positive cell populations. The geometric mean, a measure of mean fluorescence
intensity was determined, this value was multiplied with the counts for TMRE/MitoSox
positive populations to normalize the data.
Immunocytochemistry:
Prior to experiment, 25,000 cells were seeded in 35mm2 dishes overnight. On the day of
the experiment, cells were treated with mitochondrial inhibitors and stained with the
appropriate dye (TMRE or MitoSox). The cells were imaged at 40x, 3-5 images were
acquired/dish. ImageJ was used to quantify the fluorescence intensity of the images. The
integrated density, a measure of fluorescence intensity, was then divided by the area of
the image in a specific region of interest (ROI). Three ROI measurements were taken
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from dark backgrounds, in which no cells were located to determine the background
intensity. These ROI measurements were divided by their area as well. An average of the
background fluorescence intensity was taken and subtracted from those of the cells to
normalize the data.
Statistical Analysis:
All statistics and graphs were performed using GraphPad Prism 8. One-way ANOVA
with post-hoc Tukey was performed with an alpha value of 0.05 to determine statistical
significance.

Results
Mitochondrial Morphology is perturbed in tRNA mutant cell lines:
To test the hypothesis that tRNA mutation affects mitochondrial morphology, we used
MiNA to analyze mitochondrial structure and found that the number of individuals (Fig.
4a) and the number of networks (Fig. 4c) in SBG6 and SBG7 was significantly lower
than the control cell line in the presence and absence of FCCP. The mean branch length
(Fig. 4b) in SBG7 was significantly higher than the control line in the presence of FCCP.
The mean network size (Fig. 4d) of SBG7 was significantly lower than the control cell
line in the presence and absence of FCCP.
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Figure 3. Fluorescent images of the mitochondrial network of diseased and control
cell lines in the presence and absence of the mitochondrial uncoupler FCCP.
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Fibroblast cells images from diseased and control cell lines stained with MitoTracker Red
CM-H2Xros and taken under phase contrast and Red Fluorescent Protein (RFP) channels
in the presence and absence of FCCP, followed by the skeletonized image of the
fibroblast cell.

Figure 4. Mitochondrial Structure of Diseased and Healthy Fibroblast. Phase
contrast, MitoTracker Red fluorescent, and Skeletonized images of the control and
diseased cell lines. Graphs comparing the means of a)Number of Individuals, b) Mean
branch length, c) Number of networks, and d) Mean network size between the control
group and diseased cell lines in presence and absence of FCCP. Data represents 5
biological replicates for control and diseased cell lines. p* <0.05, **<0.01, ***<0.001,
and ****<0.0001
Mitochondrial Membrane Potential is lower in tRNA mutant fibroblast cell lines:
To further test the hypothesis that a defect in mitochondrial morphology could correlate
with a defect in the function of the mitochondria we recorded MMP in both tRNA mutant
and healthy control fibroblast cell lines. Flow cytometry techniques was used to evaluate
MMP, this result was further confirmed using immunocytochemistry and fluorescence
17

microscopy (Fig. 5). FCCP and Oligomycin treatments served as negative and positive
controls in this experiment. Results from this experiment suggests a trend towards
decreased MMP (Fig. 6) for both diseased cell lines relative to control.
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Figure 5. Lower fluorescent intensity observed in diseased cell lines compared to
control cell line in the presence of mitochondrial complex inhibitors. Fibroblast cells
images from diseased and control cell lines taken under phase contrast, Red Fluorescent
Protein (RFP), and DAPi channels in the presence of TMRE only, TMRE + FCCP, and
TMRE + Oligomycin.
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Figure 6. Diseased cell lines exhibit lower membrane potential than control cell line
in the presence and absence of mitochondria toxins. Histogram showing the live
TMRE positive cell population. Graphs comparing the means of the normalized mean
fluorescent intensity values for the control cell line and the diseased cell lines in the
presence of d) TMRE only, e) TMRE + FCCP, and f) TMRE + Oligomycin. Data
represents 3 biological replicates for control and diseased cell lines. p* <0.05, **<0.01,
***<0.001, and ****<0.0001

Mitochondrial ROS is not altered in tRNA mutant cell lines
Finally, to understand the relationship between mitochondrial morphology and function,
we observed mitochondrial ROS production in diseased and healthy control fibroblast
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cell lines. Flow cytometry techniques were used to evaluate MitoROS and results were
further confirmed using immunocytochemistry and fluorescence microscopy (Fig. 7). Our
results suggests a trend towards lower ROS production (Fig.8) in both diseased cell lines
relative to control cell lines, however, these differences are not statistically significant.
When we treated cells with mitochondrial inhibitors, Rotenone or AntimycinA, we found
that the mean fluorescence intensity was significantly lower in both SBG6 and SBG7
compared to the control cell line (Fig. 8 e-f).
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Figure 7. Fluorescent images of fibroblast cells in the presence of mitochondrial
complex inhibitors. Fibroblast cells images from diseased and control cell lines taken
under phase contrast, Red Fluorescent Protein (RFP), and DAPi channels in the presence
of MitoSox only, MitoSox + Rotenone, and MitoSox + AntimycinA.
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Figure 8. Diseased cell lines exhibit lower ROS production than control cell line only
in the presence of mitochondrial complex inhibitors. Histogram showing the live
MitoSox positive cell population. Graphs comparing the means of the normalized mean
fluorescent intensity values for the control cell line and the diseased cell lines in the
presence of d) MitoSox only, e) MitoSox + Rotenone, and f) MitoSox + Antimycin. Data
represents 3 biological replicates for control and diseased cell lines. p* <0.05, **<0.01,
***<0.001, and ****<0.0001
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Discussion
It has been suggested that mutations in mitochondrial DNA can lead to an
imbalance in the cycle of fission and fusion, thereby altering the morphology of the
mitochondrial network (Ni et al., 2015). We anticipated that the mutant tRNA cell lines
would exhibit a a more fragmented (particularly in the presence of FCCP) or more fused
mitochondrial network structure (Liesa & Shirihai, 2013). A hyper-fragmented network
would be expected to result in increased count of mitochondria individuals as well as
increased number of networks with subsequent decrease in mean branch length and
network size, this would be the expected result with FCCP treatment (Valente et al.,
2017). A hyper-fused network would be expected to exhibit a decreased count of
mitochondria individuals and decreased number of networks with subsequent increase in
mean branch lenth and network size. The number of individuals and the number of
networks was lower in tRNA mutant cell lines than the control with and without FCCP
treatment, suggesting a more fused network. The mean branch length was significantly
higher in SBG7, but the mean branch length of SBG6 was not significantly different from
the control. The mean network size was significantly lower in SBG7, yet SBG6 was
again not significantly different than the control. The results suggest that the tRNA
mutant cell lines exhibit a different morphology than the control cell line. While SBG7
shows a trend towards fusion, SBG6 was more like the control. The similarity between
SBG6 and healthy control could suggest that the mutation load is lower in this cell line.
Healthy mitochondria maintain a membrane potential across the inner
mitochondrial membrane in order to provide energy to drive ATP synthesis (Chen, 1988).
In addition to the structural analysis, we sought to understand if structural differences in
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these mutant cell lines would translate to functional defect. To do this we examined
mitochondrial membrane potential (MMP). Moreover, FCCP and Oligomycin were used
to serve as negative and positive controls respectively. FCCP destabilizes the proton
gradient across the inner membrane space (Brennan et al., 2006) as a result dissipating
the membrane potential. Oligomycin inhibits ATP synthase by blocking the proton pump,
thereby hyperpolarizing the membrane. (Fernyhough & McGavock, 2014). We
hypothesized that tRNA mutant cell lines would display decreased mitochondrial
function, which may be indicated by a lower mitochondrial membrane potential. Flow
cytometry analysis showed that tRNA mutant cell lines exhibited lower MMP relative to
the healthy control cell line. Since the mitochondrial tRNA is involved in translation of
proteins, enzymatic functions of many of the complexes involved in OxPhos could
potentially be perturbed, owing to incorporation of dysfunctional proteins (Pek et al.,
2019). Therefore, we anticipate that the defects caused by tRNA mutations may cause
overall decrease in OxPhos activity. This could explain our findings of reduced
membrane potential in tRNA mutant cell lines. These results do not show the typical
mitochondrial response to Oligomycin, as control cell line does not display notably
higher mitochondrial membrane potential. Further experiments will need to be conducted
in order to confirm the hyperpolarizing action of Oligomycin.
Finally, we assessed mitochondrial ROS production as a second measure of
mitochondrial function. ROS are created during normal respiration by the reduction of
oxygen (Murphy, 2009). ROS production has been reported to serve as a means of
communication between mitochondria and the nucleus in healthy cells (Murphy, 2009).
Unusually high or unusually low level of ROS can thus serve as an indicator of a diseased
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state. We would expect that mitochondrial disease would result in ROS levels that differ
from those of control. Flow cytometry analysis indicated that a trend exists towards lower
ROS production in tRNA mutant cell lines, however the results were not statisically
significant.
In order to confirm the flow cytometry data and its assertions about
mitochondrial function, we used immunocyochemistry and fluorescent microscopy to
measure mitochondrial membrane potential and ROS production. The results showed that
the tRNA mutant cell lines displayed decreased membrane potential compared to control
in all treatment groups (Supp. Fig. 1). The tRNA mutant cell lines exhibited a trend of
decreased ROS production (Supp. Fig. 2) compared to the control, but it was not
significant. This data supports our flow cytometry results.
Morphological analysis of mitochondrial structure in this study showed an
altered morphology in tRNA mutant cell lines compared to the control. The functional
analysis of diseased mitochondria indicated that tRNA mutant cell lines exhibit decreased
function in terms of mitochondrial membrane potential, but not in regards to ROS
production. Further investigation into how tRNA mutations affect the respiratory chain
could help to shed light on which aspects of the mitochondria may be directly affected. It
is worthwhile to mention that the MiNA software does not distinguish between rods and
punctate shapes, perhaps writing a code for this distinction could be beneficial in
determining the differences between diseased and healthy cell lines.
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Supplementary Figures

Supplementary Figure 1. Diseased cell lines exhibit lower membrane potential than
control cell line in the presence and absence of mitochondrial toxins. Graphs
comparing the means of the fluorescent intensity between the control and diseased cell
lines in the presence of b) TMRE only, c) TMRE + FCCP, and d) TMRE + Oligomycin.
Data represents 3 biological replicates for control and diseased cell lines. p* <0.05,
**<0.01, ***<0.001, and ****<0.0001
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Supplementary Figure 2. Diseased cell lines exhibit lower ROS production than
control cell line in the presence of mitochondrial complex inhibitors. Graphs
comparing the means of the fluorescent intensity between the control and diseased cell
lines in the presence of b) MitoSox only, c) MitoSox+Rotenone, and d)
MitoSox+AntimycinA. Data represents 3 biological replicates for control and diseased
cell lines. p* <0.05, **<0.01, ***<0.001, and ****<0.0001
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